慢性髓细胞性白血病患者移植前后Bcr-Abl融合基因检测和预处理的临床意义
摘要
异基因造血干细胞移植是治疗慢性髓细胞性白血病（chronic myelogenous leukemia,CML）的重要手段之一。目前,移植治疗相关的并发症如移植物抗宿主病（graft versushost disease,GVHD）及感染等仍是移植失败的重要因素,但多数患者仍能获得治愈。本研究回顾分析我院近年CML慢性期患者异基因造血干细胞移植前预处理方案与移植后Bcr-Abl融合基因分子生物学检测的临床意义。
出处
《诊断学理论与实践》
2007年第4期374-375,共2页
Journal of Diagnostics Concepts & Practice
参考文献10
-
1[1]Horowitz MM,Rowlings PA,PasswegJR.Allogeneic bone marrow transplantation for CML:a report from the International Bone Marrow Transplant Registry[J].Bone Marrow Transplant,1996,17(suppl 3):S5-S6.
-
2[2]Sawyers CL.Chronic myeloid leukemia[J].N Engl J Med,1999,340(17):1330-1340.
-
3[3]Hughes TP,Kaeda J,Branford S,et al.Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia[J].N Engl J Med,2003,349(15):1423-1432.
-
4[4]Kantarjian H,Sawyers C,Hochhaus A,et al.Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia[J].N Engl J Med,2002,346(9):645-652.
-
5[5]Cortes J,Talpaz M,O'Brien S,et al.Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate[J].Clin Cancer Res,2005,11 (9):3425 -3432.
-
6[6]Davies SM,DeFor TE,McGlave PB,et al.Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors[J].Am J Med,2001,110(5):339-346.
-
7[7]Crawley C,Szydlo R,Lalancette M,et al.Outcomes of reduced-intensity transplantation for chronic myeloid leukemia:an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT[J].Blood,2005,106(9):2969-2976.
-
8[8]Or R,Shapira MY,Resnick I.Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase[J].Blood,2003,101(2):441-445.
-
9[9]Radich JP,Gooley T,Bryant E,et al.The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation[J].Blood,2001,98(6):1701-1707.
-
10[10]Press RD,Love Z,Tronnes AA,et al.Bcr-Abl mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML[J].Blood,2006,107(11):4250-4256.
-
1朱飞跃.干扰素联合达沙替尼治疗慢性粒细胞白血病的疗效探讨[J].当代医学,2015,21(11):5-6. 被引量：1
-
2陈炜.伊马替尼治疗慢性髓细胞性白血病不良反应的效果观察[J].中国医药指南,2016,14(26):114-115.
-
3陈德福,钱林生.α干扰素在多发性骨髓瘤治疗中的应用价值[J].天津医药,2003,31(2):126-128. 被引量：1
-
4阮国瑞,刘艳荣,陈珊珊,李金兰,秦亚溱,付家瑜,白任奎.成人慢性髓性白血病骨髓细胞血管内皮生长因子的表达[J].中国实验血液学杂志,2001,9(1):5-9. 被引量：7
-
5郭素青,李英华.慢性髓系白血病急性转化中基因组的不稳定[J].中国实验血液学杂志,2015,23(4):1199-1202.
-
6王兴丽,杨文华,史哲新,刘宝山,高宏.慢性粒细胞白血病分子靶向治疗研究进展[J].浙江中西医结合杂志,2012,22(3):241-242. 被引量：5
-
7谭向荣(综述),葛明华(审校).头颈部鳞癌手术切缘分子标记物[J].国际肿瘤学杂志,2009,36(12):914-917.
-
8陈燕.细胞遗传学及分子生物学检测在慢性粒细胞白血病中的临床意义[J].中国医刊,1999,34(9):7-9.
-
9杨学全 ,纪维义 .乳腺癌癌前病变诊断及治疗[J].中国煤炭工业医学杂志,2004,7(1):1-2. 被引量：1
-
10张旭霞,孙延庆,魏小芳,李红玲,张启科.大黄素对人慢性髓细胞性白血病K562细胞增殖与凋亡及c-myc基因表达的影响[J].中华肿瘤防治杂志,2009,16(20):1541-1545. 被引量：12
